MannKind (NASDAQ:MNKD) issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.01, Bloomberg Earnings reports. The firm had revenue of $4.53 million for the quarter, compared to analyst estimates of $3.22 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 999.00%.
MannKind (NASDAQ MNKD) traded down $0.03 during trading hours on Tuesday, hitting $2.81. The company had a trading volume of 2,181,825 shares, compared to its average volume of 4,550,955. The company has a debt-to-equity ratio of -0.48, a quick ratio of 0.62 and a current ratio of 0.65. MannKind has a 12 month low of $0.67 and a 12 month high of $6.96. The company has a market cap of $323.37, a price-to-earnings ratio of -2.51 and a beta of 2.95.
MNKD has been the topic of several research reports. HC Wainwright restated a “buy” rating on shares of MannKind in a research note on Wednesday, November 8th. ValuEngine lowered MannKind from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research upgraded MannKind from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. BidaskClub lowered MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Finally, Maxim Group reiterated a “hold” rating on shares of MannKind in a research note on Tuesday, January 30th. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. MannKind presently has an average rating of “Hold” and a consensus target price of $1.59.
In related news, VP Stuart A. Tross acquired 39,840 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were bought at an average cost of $2.52 per share, for a total transaction of $100,396.80. Following the purchase, the vice president now owns 59,840 shares in the company, valued at approximately $150,796.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.10% of the company’s stock.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.